NasdaqGM:NLNK

Stock Analysis Report

Executive Summary

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has NewLink Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.0%

NLNK

4.6%

US Biotechs

3.4%

US Market


1 Year Return

-37.4%

NLNK

-10.1%

US Biotechs

5.4%

US Market

Return vs Industry: NLNK underperformed the US Biotechs industry which returned -10.1% over the past year.

Return vs Market: NLNK underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

NLNKIndustryMarket
7 Day15.0%4.6%3.4%
30 Day-29.6%-2.4%-1.0%
90 Day-16.5%-2.1%-0.4%
1 Year-37.4%-37.4%-9.4%-10.1%7.7%5.4%
3 Year-90.9%-90.9%14.9%10.9%46.2%36.8%
5 Year-96.6%-96.6%2.3%-2.7%65.6%47.5%

Price Volatility Vs. Market

How volatile is NewLink Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NewLink Genetics undervalued compared to its fair value and its price relative to the market?

0.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate NLNK's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NLNK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NLNK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: NLNK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NLNK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NLNK is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is NewLink Genetics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-20.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NLNK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NLNK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NLNK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NLNK's revenue (21.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: NLNK's revenue (21.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if NLNK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NewLink Genetics performed over the past 5 years?

-33.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NLNK is unprofitable, and losses have increased over the past 5 years at a rate of -33% per year.

Accelerating Growth: Unable to compare NLNK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NLNK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: NLNK has a negative Return on Equity (-38.65%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NLNK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NLNK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is NewLink Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: NLNK's short term assets ($110.2M) exceeds its short term liabilities ($8.6M)

Long Term Liabilities: NLNK's short term assets (110.2M) exceeds its long term liabilities (13.5M)


Debt to Equity History and Analysis

Debt Level: NLNK's debt to equity ratio (0.07%) is considered satisfactory

Reducing Debt: NLNK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: NLNK has a low level of unsold assets or inventory.

Debt Coverage by Assets: NLNK's debt is covered by short term assets (assets are 1489.162160x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NLNK has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NLNK has sufficient cash runway for 2.526098 years if free cash flow continues to grow at historical rates of 19.7% each year.


Next Steps

Dividend

What is NewLink Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NLNK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NLNK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NLNK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NLNK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NLNK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of NewLink Genetics's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

NewLink Genetics has no CEO, or we have no data on them.


Management Age and Tenure

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: NLNK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: NLNK's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mario Mautino (53yo)

    Senior VP of Drug Discovery & Intellectual Property Officer

    • Tenure: 0yrs
  • Carl Langren (64yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.3yrs
    • Compensation: US$842.81k
  • Gene Kennedy (50yo)

    Chief Medical Officer

    • Tenure: 1.9yrs
    • Compensation: US$1.21m
  • Lisa Miller

    Director of Investor Relations

    • Tenure: 0yrs
  • Lori Lawley

    VP of Finance & Controller

    • Tenure: 1.3yrs
  • Brad Powers

    General Counsel

    • Tenure: 1.3yrs

Board Members

  • Lota Zoth (59yo)

    Independent Director

    • Tenure: 6.9yrs
    • Compensation: US$181.13k
  • Tom Raffin (72yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$204.26k
  • Matt Sherman (63yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$358.92k
  • Ernest Talarico (48yo)

    Independent Director

    • Tenure: 20.8yrs
    • Compensation: US$175.00k
  • Chad Johnson (40yo)

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$393.32k

Company Information

NewLink Genetics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NewLink Genetics Corporation
  • Ticker: NLNK
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$50.186m
  • Shares outstanding: 37.31m
  • Website: https://www.newlinkgenetics.com

Number of Employees


Location

  • NewLink Genetics Corporation
  • 2503 South Loop Drive
  • Suite 5100
  • Ames
  • Iowa
  • 50010
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NLNKNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2011
4NXDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011

Biography

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:12
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.